A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician’s attitude

References

• Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K. Adult Pneumonia Study Group-Japan (APSG-J). The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One. 2015;10:e0122247. doi:10.1371/journal.pone.0122247. PMID: 25822890.
   PubMed Web of Science ®Google Scholar
• Jauneikaite E, Tocheva AS, Jefferies JM, Gladstone RA, Faust SN, Christodoulides M, Hibberd ML, Clarke SC. Current methods for capsular typing of Streptococcus pneumoniae. J Microbiol Methods. 2015;113:41–49. doi:10.1016/j.mimet.2015.03.006. PMID: 25819558.
   PubMed Web of Science ®Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79. doi:10.1136/thx.2009.129502. PMID: 20729232.
   PubMed Web of Science ®Google Scholar
• Peto L, Nadjm B, Horby P, Ngan TT, van Doorn R, Van Kinh N, Wertheim HF, Peto L, Nadjm B, Horby P, et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. T Roy Soc Trop Med H. 2014;108:326–37. doi:10.1093/trstmh/tru058. PMID: 24781376.
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG. CDC EPIC study team. Community-acquired pneumonia requiring hospitalization among US adults. New Engl J Med. 2015;373:415–27. doi:10.1056/NEJMoa1500245. PMID: 26172429.
   PubMed Web of Science ®Google Scholar
• Ministry of health, labour and welfare. Pneumococcal infection (elderly person). [accessed 2019 Aug 9]. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/haienkyukin/index_1.html.
   Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X. Hospital-Guardiola. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014;58:909–17. doi:10.1080/21645515.2016.1210744. PMID: 27454779.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802–08. doi:10.1016/j.vaccine.2012.09.019. PMID: 23000122.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine. 2011;29:2287–95. doi:10.1016/j.vaccine.2011.01.029. PMID: 21255685.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281:243–48. doi:10.1001/jama.281.3.243. PMID: 9918479.
   PubMed Web of Science ®Google Scholar
• Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review. BMC Infect Dis. 2016;16:711. doi:10.1186/s12879-016-2040-y. PMID: 27887596.
   PubMed Web of Science ®Google Scholar
• Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory committee on immunization practices recommended immunization schedule for adults Aged 19 years or older - United States, 2017. Mmwr-Morbid Mortal W. 2017;66:136–38. doi:10.15585/mmwr.mm6605e2. PMID: 28182599.
   PubMed Web of Science ®Google Scholar
• The Japanese Association for Infectious Diseases (JAID). Guideline for revaccination of pneumococcal vaccine. [accessed 2019 Aug 9]. http://www.kansensho.or.jp/uploads/files/guidelines/pneumococcus_vaccine.pdf.
   Google Scholar
• Kawakami K, Kishino H, Kanazu S, Toshimizu N, Takahashi K, Sterling T, Wang M, Musey L. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine. 2016;34:3875–81. doi:10.1016/j.vaccine.2016.05.052. PMID:27265450.
   PubMed Web of Science ®Google Scholar
• Ohshima N, Nagai H, Matsui H, Akashi S, Makino T, Akeda Y, Oishi K. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Vaccine. 2014;32:1181–86. doi:10.1016/j.vaccine.2013.09.060. PMID: 24120483.
   PubMed Web of Science ®Google Scholar
• The Japanese Association for Infectious Diseases (JAID). Guidance for revaccination of pneumococcal vaccine (revised edition). J Jpn Assoc Infect Dis. 2017;91(4):543–52. [accessed 2019 Aug 9]. http://www.kansensho.or.jp/uploads/files/guidelines/pneumococcus_vaccine_re_1707.pdf.
   Google Scholar
• Naito T, Yokokawa H, Watanabe A. Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan. J Infect Chemother. 2018;24:496–98. doi:10.1016/j.jiac.2018.01.004. PMID: 29398479.
   PubMed Web of Science ®Google Scholar
• Shono A, Hoshi SL, Kondo M. The impact on vaccination coverage rate following introduction of a routine pneumococcal vaccination programme for the elderly in Japan. Vaccine. 2018;36:5886–90. doi:10.1016/j.vaccine.2018.08.023. PMID: 30143271.
   PubMed Web of Science ®Google Scholar
• Thomas HL, Gajraj R, Slack MP, Sheppard C, Hawkey P, Gossain S, Drew CM, Pebody RG. An explosive outbreak of Streptococcus pneumoniae serotype-8 infection in a highly vaccinated residential care home, England, summer 2012. Epidemiol Infect. 2015;143:1957–63. doi:10.1017/S0950268814002490. PMID: 25298247.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kishino H, Kanazu S, Takahashi K, Iino T, Sawata M, Musey L. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly. Hum Vacc Immunother. 2018;14:1931–38. doi:10.1080/21645515.2018.1456611. PMID: 29580133.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, et al. Adult Pneumonia Study Group-Japan (APSG-J). Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17:313–21. doi:10.1016/S1473-3099(17)30049-X. PMID: 28126327.
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Chanyasanha C, Sujirarat D, Matsumoto N, Nakazato M. Factors associated with pneumococcal vaccination in elderly people: a cross-sectional study among elderly club members in Miyakonojo City, Japan. BMC Public Health. 2018;18:1172. doi:10.1186/s12889-018-6080-7. PMID: 30314498.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Hospital I, de Diego C, Satué E, Bladé J, Ansa X, Guzmán JA, Salsench E, Ramos F. Pneumococcal vaccination coverage rates among low-, intermediate-, and high-risk adults in Catalonia. Hum Vacc Immunother. 2016;12:2953–58. doi:10.1080/21645515.2016.1210744. PMID: 27454779.
   PubMed Web of Science ®Google Scholar
• Liu SJ, Xu EP, Liu Y, Xu Y, Wang J, Du J, Zhang X, Che X, Gu W. Factors associated with pneumococcal vaccination among an urban elderly population in China. Hum Vacc Immunother. 2014;10:2994–99. doi:10.4161/21645515.2014.972155. PMID: 25483646.
   PubMed Web of Science ®Google Scholar
• Oishi K, Kawakami K, Nagai H, Sunakawa K, Watanabe A. [A questionnaire study on the necessity of approval for revaccination of the pneumococcal polysaccharide vaccine]. Nihon Kokyuki Gakkai Zasshi. 2010;48:5–9. PMID: 20163014.
   PubMedGoogle Scholar
• Ministry of Health, Labour and Welfare. Coverage rates of national immunization program published by Japanese ministry of health, labour and welfare. [accessed 2019 Aug 9]. https://www.mhlw.go.jp/topics/bcg/other/5.html.
   Google Scholar